Biao Lu

Dr. Biao Lu

Department of Bioengineering, School of Engineering, Santa Clara University, 500 El Camino Real, Santa Clara, CA 95053, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2016 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
ZSZachary Stickney
Zachary Stickney
JLJoseph Losacco
Joseph Losacco
SMSophie McDevitt
Sophie McDevitt
ZZZhiwen Zhang
Zhiwen Zhang
Biao LuBiao Lu
Biao Lu

1 April 2017 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
CMConary Meyer
Conary Meyer
JLJoseph Losacco
Joseph Losacco
ZSZachary Stickney
Zachary Stickney
LLLingxuan Li
Lingxuan Li
GMGerard Marriott
Gerard Marriott
Biao LuBiao Lu
Biao Lu
Exosomes are cell-derived nanovesicles that hold promise as living vehicles for intracellular delivery of therapeutics to mammalian cells. This potential, however, is undermined by the lack of effective methods to load exosomes with therapeutic proteins and to facilitate their uptake by target cells. Here, we demonstrate how a vesicular stomatitis virus glycoprotein (VSVG) can both load protein cargo onto exosomes and increase their delivery ability via a pseudotyping mechanism. By fusing a set of fluorescent and luminescent reporters with VSVG, we show the successful targeting and incorporation of VSVG fusions into exosomes by gene transfection and fluorescence tracking. We subsequently validate our system by live cell imaging of VSVG and its participation in endosomes/exosomes that are ultimately released from transfected HEK293 cells. We show that VSVG pseudotyping of exosomes does not affect the size or distributions of the exosomes, and both the full-length VSVG and the VSVG without the ectodomain are shown to integrate into the exosomal membrane, suggesting that the ectodomain is not required for protein loading. Finally, exosomes pseudotyped with full-length VSVG are internalized by multiple-recipient cell types to a greater degree compared to exosomes loaded with VSVG without the ectodomain, confirming a role of the ectodomain in cell tropism. In summary, our work introduces a new genetically encoded pseudotyping platform to load and enhance the intracellular delivery of therapeutic proteins via exosome-based vehicles to target cells.

21 November 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MDMai Anh Do
Mai Anh Do
DLDaniel Levy
Daniel Levy
ABAnnie Brown
Annie Brown
GMGerard Marriott
Gerard Marriott
Biao LuBiao Lu
Biao Lu
Targeted delivery of lysosomal enzymes to the endocytic compartment of human cells represents a transformative technology for treating a large family of lysosomal storage diseases (LSDs). Gaucher disease is one of the most common types of LSDs caused by mutations to the lysosomal β-glucocerebrosidase (GBA). Here, we describe a genetic strategy to produce engineered exosomes loaded with GBA in two different spatial configurations for targeted delivery to the endocytic compartment of recipient cells. By fusing human GBA to an exosome-anchoring protein: vesicular stomatitis virus glycoprotein (VSVG), we demonstrate that the chimeric proteins were successfully integrated into exosomes which were secreted as extracellular vesicles (EVs) by producer cells. Isolation and molecular characterization of EVs confirmed that the fusion proteins were loaded onto exosomes without altering their surface markers, particle size or distribution. Further, enzyme-loaded exosomes/EVs added to cultured medium were taken up by recipient cells. Further, the endocytosed exosomes/EVs targeted to endocytic compartments exhibited a significant increase in GBA activity. Together, we have developed a novel method for targeting and delivery of lysosomal enzymes to their natural location: the endocytic compartment of recipient cells. Since exosomes/EVs have an intrinsic ability to cross the blood-brain-barrier, our technology may provide a new approach to treat severe types of LSDs, including Gaucher disease with neurological complications.

19 May 2020 in Nanoscale
Verified
Journal Article
Closed access
PDF file
NCNatalie Curley
Natalie Curley
DLDaniel Levy
Daniel Levy
MDMai Anh Do
Mai Anh Do
ABAnnie Brown
Annie Brown
ZSZachary Stickney
Zachary Stickney
Biao LuBiao Lu
Biao Lu
The native exosome transmembrane protein, CD63 can be modified for surface engineering applications.

1 May 2019 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
NDNatalie Duong
Natalie Duong
KCKevin Curley
Kevin Curley
ABAnnie Brown
Annie Brown
ACAlexander Campanelli
Alexander Campanelli
MDMai Anh Do
Mai Anh Do
Biao LuBiao Lu
Biao Lu
Background: Exosomes are ubiquitous naturally secreted stable nanovesicles that can be engineered to target and deliver novel therapeutics to treat a host of human diseases. Methods: We engineered the surfaces of cell-derived nanovesicles to act as decoys in the treatment of inflammation by antagonizing the major proinflammatory cytokine, tumor necrosis factor alpha (TNFα). Results: Decoy exosomes were generated by displaying the TNFα binding domain of human TNF receptor-1 (hTNFR1) on the outer surface of exosomes using stably transfected HEK293 cells. We developed an efficient method to purify the engineered exosomes from conditioned medium based on sequential centrifugation, ultrafiltration, and precipitation. We characterized decoy exosomes using immune-quantification, nanoparticle tracking analysis, and confocal microscopy to confirm that they retain the correct orientation, size, and shape of naturally produced exosomes. We demonstrated the engineered decoy exosomes specifically antagonize activities of TNFα using an inflammatory reporter cell line. Conclusions: Decoy exosomes produced in human cells serve as a novel biologic reagent for antagonizing inflammatory signaling mediated by TNFα.

22 July 2022 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
Biao LuBiao Lu
Biao Lu
JKJoy Ku
Joy Ku
RFRenceh Flojo
Renceh Flojo
COChris Olson
Chris Olson
DBDavid Bengford
David Bengford
GMGerard Marriott
Gerard Marriott